Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Natural Method for Clearing Cellular Debris Inspires Lupus Treatment

By BiotechDaily International staff writers
Posted on 06 Mar 2012
Cells that die naturally generate a large amount of internal debris that can trigger the immune system to attack the body, leading to diseases such as lupus. Now, researchers report that an enzyme known to help keep a woman’s immune system from attacking a fetus also helps block development of these autoimmune diseases that target healthy tissues.

The study’s findings lead to toward new treatment approaches for autoimmune diseases, which are increasing in light of a germ-conscious society that regularly destroys many of the previously pervasive microbes that made the immune system more tolerant. “The basic premise of lupus is you have lost normal tolerance to yourself, your own proteins, and DNA,” said Dr. Tracy L. McGaha, Georgia Health Sciences University (GHSU; Augusta, USA) immunologist and corresponding author of the study published ahead of print February 21, 2012, in the journal Proceedings of the [US] National Academy of Sciences.

The investigators discovered that IDO, or indoleomine 2,3-dioxegenase, helps promote tolerance to debris generated by natural cell death and that when IDO is removed from the mixture, the debris triggers an immune response that can induce autoimmune disease. In mice genetically engineered to develop lupus, blocking IDO resulted in earlier, more aggressive disease. “This connects IDO and macrophages. It’s a newly described role for IDO in regulation of tolerance toward self,” Dr. McGaha remarked. Accordingly, increasing IDO production or its downstream effects might be a way to regain lost tolerance, he said.

The researchers assessed activity in the spleen; a hard-working immune organ that constantly filters blood. In a flawlessly organized defense, the entrance to the spleen is surrounded by immune cells that search the blood for viruses, bacteria, even fat and cholesterol floating by.

A neighboring subset of macrophages, which are basically scavengers, then capture and consume the undesirables, according to Dr. McGaha said. Fascinatingly, a lot of what macrophages consume is dead immune cells.

Macrophages also appear to help keep the peace by preventing the immune system from joining the fray. Dr. McGaha earlier found that if he destroyed macrophages, then fed the spleen dead cells, there was inflammation instead of calm. “That tells us there is something inherent in this subset of macrophages that is important for the suppressive process,” Dr. McGaha said referencing the study published in 2011 in the journal Blood.

The new study revealed that IDO is part of that “something.” Efficient elimination of cell debris while keeping nearby immune cells quiet is important because some debris is known to grab the attention of the immune system, According to Dr. McGaha. He noted that it is normal--and healthy--for damaged cells to become targets. “We are really interested in this process of normal cell debris removal because in lupus, it's thought to be one of the main drivers of inflammation,” he said.

The immune system has points of expansion and regulation where it decides whether or not to act. Knowing key points, such as IDO’s regulatory role, provides treatment targets that can interrupt a destructive cascade of immune activity, Dr. McGaha noted. Earlier research has shown evidence of self-attack is present many years before disease symptoms appear, he said.

Environmental hazards, such as a nasty sunburn, can be the first trigger of the abnormal immune response in diseases such as lupus. In healthy individuals, the immune system rises to the occasion of an infection then goes back to baseline. In autoimmune disease, patients tend not to return to normal levels.

GHSU’s Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Following studies have shown tumors also use it and that it could help transplanted organs escape rejection. They suggested that Dr. McGaha evaluate IDO as a regulatory process used by macrophages.

Related Links:
Georgia Health Sciences University



view channel
Image: Micrograph showing immunofluorescence of skin differentiation markers for basal keratinocytes (Photo courtesy of Dr. Russ Carstens, University of Pennsylvania).

Alternate Splicing Proteins Critically Linked to Skin and Organ Development

Two proteins that regulate alternative splicing in epithelial cells have been linked to the proper development of the skin and protective layers that surround other organs in the body. Two steps are... Read more

Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.